Navigation Links
Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients

PHILADELPHIA, Jan. 24, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.

"We are very excited to initiate patient enrollment in our next studies of the Symphony system in the important hospital critical care setting," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "The goal of these trials is to demonstrate Symphony's performance in the large and emerging critical care market for non-invasive continuous glucose monitoring. We believe that Symphony addresses this unmet need, potentially improving patient outcomes."

Echo's clinical studies will enroll up to thirty (30) critical care patients and will compare data obtained from its Symphony tCGM System with the YSI 2300 STAT Plus Glucose Analyzer.  The studies are expected to collect more than 1,000 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours.  The data from the studies will be blinded to study subjects and study personnel. A comparison of the data relative to the blood glucose values will be used to assess the accuracy of Symphony.

About Continuous Glucose Monitoring in Critical Care

Hyperglycemia is common in critically ill patients, even in those that do not have a history of diabetes. Intensive insulin therapy and frequent glucose monitoring in critically ill patients has been proven in clinical studies to significantly reduce patient morbidity and mortality.  Intensive insulin therapy requires frequent, often hourly, nurse intervention to monitor blood glucose and adjust insulin administration to avoid hypoglycemia. The potential benefits of accurate continuous glucose monitoring in critical care are widely recognized.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including: the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems; the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems; Echo's ability to secure additional commercial partnering arrangements; risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems; the availability of substantial additional funding to support its research, development and product commercialization activities; and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Forms 10-Q, and its Current Reports on Forms 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
2. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
3. Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
4. Lightlake Therapeutics Inc. to Apply Companys Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
5. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
6. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
7. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
8. Echo Therapeutics Announces $3.6 Million Warrant Exercises
9. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
10. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
11. AuraSense Therapeutics Secures Series B Equity Investment
Post Your Comments:
(Date:10/13/2015)... Ga. , Oct. 13, 2015  EndoChoice Holdings, ... its third quarter 2015 financial results on Thursday, November ... . --> . ... on Thursday, November 5, 2015 at 9:00 a.m. ET ... 328-5344 for domestic callers and (412) 317-5469 for international ...
(Date:10/13/2015)... --> --> ... from the Asthma and COPD Therapies market? Which areas are ... brand new report shows you potential revenues to 2025, assessing ... provides 260 tables, charts, and graphs. Discover the most lucrative ... new study lets you assess forecasted sales at overall world ...
(Date:10/13/2015)... 13, 2015  XiMo AG ( Lucerne ... Inc. ( Milpitas, California ) announced today ... chemistry. The importance of metathesis chemistry was highlighted by ... of this application. This industrially-relevant application has been utilized ... pharmaceuticals, specialty chemicals, and polymers. Georg Fráter ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... companies in the United States, today announced the release of its limited edition ... new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and delicious ...
(Date:10/13/2015)... Hills, CA (PRWEB) , ... October 13, 2015 ... ... management and workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, ... Reno-Tahoe, Nevada. AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences ...
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West ... 18, 2015. The research, which was conducted at the Dental Institute at King's College ... connections between stress during pregnancy and future dental health in the child. For years, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. You need ... blood. But how much protein does the average man need in order to stay ... the October 2015 issue of Harvard Men's Health Watch . Most Americans get ...
(Date:10/13/2015)... GA (PRWEB) , ... October 13, 2015 , ... ... nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along with ... announce the collective schedule for their regional telehealth summits for Fall 2015. ...
Breaking Medicine News(10 mins):